| 哮喘治疗的潜在新靶点:T细胞免疫球蛋白粘蛋白分子-3 |
| |
| 引用本文： | 翁晓静,张洪泉. 哮喘治疗的潜在新靶点:T细胞免疫球蛋白粘蛋白分子-3[J]. 国际药学研究杂志, 2007, 34(4): 267-270 |
| |
| 作者姓名： | 翁晓静 张洪泉 |
| |
| 作者单位： | 扬州大学医药研究所,江苏,扬州,225001;扬州大学医药研究所,江苏,扬州,225001 |
| |
| 摘 要： | T 细胞免疫球蛋白粘蛋白分子-3 (Tim-3)通过与CD4+ CD25+调节性T细胞和(或)抗原提呈细胞上表达的Tim-3配体相互作用，抑制Th1免疫应答，在哮喘等免疫性疾病中发挥重要作用。由于Tim-3与哮喘的高度相关性，其可能成为哮喘治疗的新靶点。
|
| 关 键 词： | 哮喘 T细胞免疫球蛋白粘蛋白分子-3 基因治疗 |
| 收稿时间： | 2006-12-14 |
A new potential target of asthma therapy: T cell immunoglobulin-and mucin-domain-containing molecule-3 |
| |
| WENG Xiao-jing,ZHANG Hong-quan. A new potential target of asthma therapy: T cell immunoglobulin-and mucin-domain-containing molecule-3[J]. Foreign Medical Sciences(Section of Pharmarcy), 2007, 34(4): 267-270 |
| |
| Authors: | WENG Xiao-jing ZHANG Hong-quan |
| |
| Affiliation: | （Medical and Pharmaceutical Institute, Yangzhou University, Yangzhou 225001, China） |
| |
| Abstract: | T cell immunoglobulin-and mucin-domain-containing molecule-3 (Tim-3) acts as a negative regulator of Th1 responses by a cognate interaction with its potential ligand on CD4+ CD25+ regulatory T cells and/or antigen presenting cells. Tim-3 pathway has been shown to inhibit Th1 mediated auto-and allo-immune responses and to facilitate the development of asthma. It is possible that Tim-3 gene would be the new target in asthma therapy because it is highly relevant to asthma. |
| |
| Keywords: | asthma T cell immunoglobulin-and mucin-domain-containing molecule-3 gene therapy |
| 本文献已被 万方数据 等数据库收录！ |
| 点击此处可从《国际药学研究杂志》浏览原始摘要信息 |
|
点击此处可从《国际药学研究杂志》下载全文 |
